The prevalence of chlamydial antibodies in sexually active individuals is high. A number of studies utilizing the microimmunofluorescence test have reported seroprevalence rates ranging from 50 to 80% for individuals who are culture negative for C. trachomatis to 80 to 100% for individuals who are culture positive (21, 27) . More specifically, human sera have been shown to contain antibodies to proteins of 15 serovars of C. trachomatis (14) . In the absence of functional complement (heat inactivation), only high-titered human sera neutralize C. trachomatis (12) , but in the presence of complement, lower-titered sera (for example, fresh normal human sera) are capable of diminishing the infectivity of certain C. trachomatis serovars (5, 12, 15 In the presence of antibody and complement, bacteriolysis takes place by membrane attack complexes (CSb-9) which require the late components of complement (6, 25) . To determine the possible contribution of the direct bacteriolytic effect of antibody and complement to neutralization, we examined the ability of C8-depleted (C8D) and CS-depleted (CSD) sera to neutralize C. trachomatis infectivity; neither serum had detectable hemolytic activity (50% classical hemolytic complement, < 10 U; 50% alternative hemolytic complement, <5 U). As shown in Table 2 , fresh CSD serum significantly neutralized more infectivity than heated CSD serum; 99% neutralization versus 56% for serovar K (P < The two pathways of complement converge at C3, resulting in the cleavage of C3 to C3b by C3 convertases. C3 is the most abundant complement protein in blood and plays a central role in the activation sequence of the complement system (26) . Neutralization of C. trachomatis infectivity in C5D serum, as shown above, may result from binding of C3b or its cleavage products (e.g., iC3b, C3c, or C3dg) to C. trachomatis-antibody complexes (19, 26) . We used CVF as an analog of human C3b (cobra C3b, structurally resembling the C3c fragment [2] ) to stimulate the direct contribution of human C3b in neutralizing C. trachomatis. When CVF (50 U/ml) was added to heat-inactivated human serum, neutralization of serovar K but not of serovar L2 was enhanced significantly (Table 3) . No neutralization was observed when we used a lower concentration of CVF (12.5 U/ml). Neutralization of serovar K was similarly enhanced when CVF was added to immunoglobulin fractions isolated from human serum by ammonium sulfate precipitations (data not shown).
We have examined interactions of C. trachomatis EBs and human antibodies and have demonstrated neutralization of chlamydial infectivity in vitro. This neutralization occurs in the absence of aggregation in normal human serum (lOb) and (16) . Another study showed that a serovar-specific monoclonal antibody to the major outer membrane protein of serovar L2 capable of neutralizing chlamydial infectivity abrogated ATPase activity of EBs (17) . Monoclonal antibodies to serovar-and subspecies-specific epitopes of the major outer membrane protein also neutralize chlamydial infectivity (of serovar B) by blocking chlamydial attachment to hamster kidney cells (23) . Identification of epitopes recognized by these antibodies may help to clarify biologic functions of these target antigens.
We have shown here that the late complement components were not required to enhance neutralization of chlamydial infectivity. Neutralization by the early complement components in vitro may be similar to neutralization of viral infectivity that results from the encapsulation of viral particles with antibody and complement (4) . This occurs upon activation of complement via the classical pathway of complement through C4 and occurs in the absence of detectable viral agglutination or lysis (4). In our studies, serovar L2 appears less sensitive than serovar K to complement-enhanced neutralization of normal human sera, as previously shown to be the case with sera from patients infected with serovar L2 (18) .
The protective role of antibody in host defense against the mouse pneumonitis agent (MoPn; murine C. trachomatis) has been shown previously (28) . Immune serum given intranasally delayed or prevented death in mice, and IgG or IgA fractions from immune serum or immune bronchial lavage fluid were effective in producing protection when used to opsonize MoPn. Furthermore, C5D mice were not more sensitive to MoPn than the appropriate control mice. Injection of CVF, which also depletes terminal components of complement, does not increase susceptibility to MoPn (28 
